The impact of different spirometric definitions on the prevalence of airway obstruction and their association with respiratory symptoms by Meteran, Howraman et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The impact of different spirometric definitions on the prevalence of airway obstruction
and their association with respiratory symptoms
Meteran, Howraman; Miller, Martin R; Thomsen, Simon Francis; Christensen, Kaare;
Sigsgaard, Torben; Backer, Vibeke
Published in:
ERJ Open Research
DOI:
10.1183/23120541.00110-2017
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Meteran, H., Miller, M. R., Thomsen, S. F., Christensen, K., Sigsgaard, T., & Backer, V. (2017). The impact of
different spirometric definitions on the prevalence of airway obstruction and their association with respiratory
symptoms. ERJ Open Research, 3(4), [00110-2017]. https://doi.org/10.1183/23120541.00110-2017
Download date: 03. Feb. 2020
The impact of different spirometric
definitions on the prevalence of airway
obstruction and their association with
respiratory symptoms
Howraman Meteran1, Martin R. Miller2, Simon Francis Thomsen3,4,
Kaare Christensen5, Torben Sigsgaard6 and Vibeke Backer1
Affiliations: 1Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark. 2Institute of
Occupational and Environmental Medicine, University of Birmingham, Birmingham, UK. 3Dept of Dermatology,
Bispebjerg University Hospital, Copenhagen, Denmark. 4Dept of Biomedical Sciences, University of
Copenhagen, Copenhagen, Denmark. 5The Danish Twin Registry, Epidemiology, Institute of Public Health,
University of Southern Denmark, Odense, Denmark. 6Dept of Public Health, Section of Environment
Occupation and Health, Danish Ramazzini Centre, University of Aarhus, Aarhus, Denmark.
Correspondence: Howraman Meteran, Respiratory Research Unit, Bispebjerg University Hospital, Bispebjerg
Bakke 23, Copenhagen 2400, Denmark. E-mail: hmeteran@gmail.com
ABSTRACT The fixed ratio criterion of forced expiratory volume in 1 s/forced vital capacity <0.70 for
diagnosing airway obstruction may overdiagnose the condition, particularly in the elderly, so the lower
limit of normal (LLN) is recommended as the most appropriate criterion. Our aim was to compare LLN
versus fixed ratio on the prevalence of chronic obstructive pulmonary disease (COPD) and examine the
association between respiratory symptoms and airway obstruction defined by LLN and fixed ratio.
12449 twins aged 40–80 years participated in a nationwide survey using the Danish Twin Registry. They
completed a questionnaire, underwent clinical examination and recorded prebronchodilator spirometry.
Individuals with self-reported asthma were excluded. Clinical COPD was defined by respiratory symptoms
together with airway obstruction.
10329 individuals were included, with a mean±SD age of 58.4±9.6 years and mean body mass index of
26.6±4.4 kg·m−2; 20% were current smokers, 37% former smokers and 43% never-smokers; and 48% were
male. The prevalence of LLN airway obstruction (LLN-AO) and fixed ratio airway obstruction (FR-AO)
was 5.6% and 18.0%, respectively (p<0.001). Overall, 26% reported current respiratory symptoms, but 50%
of those with LLN-AO had respiratory symptoms compared to 39% with FR-AO, p<0.001. The prevalence
of clinical LLN-COPD and fixed ratio COPD was 2.6% and 6.3%, respectively (p<0.001). Individuals with
LLN-AO had a significantly higher probability of reporting respiratory symptoms compared with both
healthy individuals and FR-AO when adjusted for sex, age and ever-smoking.
The use of fixed ratio more than doubled the prevalence of clinical COPD compared with LLN, this
being more pronounced with increased age, and identified subjects with a lower prevalence of respiratory
symptoms than LLN-AO.
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Introduction
Chronic obstructive pulmonary disease (COPD) poses a challenge for public health worldwide and has
been estimated to be the third leading cause of death in 2030 [1]. The Global Initiative for Chronic
Obstructive Lung Disease (GOLD) recommends the use of a fixed postbronchodilator forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio of <0.7 for the diagnosis of COPD [2]. This
method has been criticised, as it does not take the age-dependent decline in FEV1/FVC into account [3].
Furthermore, the fixed ratio has been shown to both underdiagnose airway obstruction (particularly in
young females) and overdiagnose it (particularly in older males) [3–10], with the latter group posing a
great challenge, as older patients with shortness of breath may have nonpulmonary causes for their
dyspnoea [11–13].
Since 2005 the American Thoracic Society (ATS) and the European Respiratory Society (ERS) have
recommended the use of lower limit of normal (LLN) for FEV1/FVC to define airway obstruction as a
z-score of <−1.645 in studies with an a priori probability of abnormality and a z-score of <−1.96 in
epidemiological studies [14, 15]. There is no consensus in the literature on the prevalence of airway
obstruction defined by the different spirometric criteria and varying estimates have been reported for both
the fixed ratio and LLN [11, 16–22].
The Danish Twin Registry and collaborators from different research units conducted a large
population-based survey of randomly selected adult twins with various aims. For this study we used these
data to examine the impact of the spirometric criteria on the prevalence of airway obstruction and to look
at the association between respiratory symptoms and fixed ratio airway obstruction (FR-AO) and LLN
airway obstruction (LLN-AO).
Methods
Study participants
All individuals included in this study participated in the Infrastructure Initiative 2008–2011, which is a
nationwide umbrella project of Danish twin individuals born 1931–1969. The clinical examinations took
place in the three largest cities in Denmark: Copenhagen, Aarhus and Odense [23]. The population for the
current study is based on two cohorts from middle-aged Danish twins (MADT) from the Danish twin
register, consisting of 2402 individuals born 1931–1952, and a further 10281 individuals born 1931–1969
(MIDT). The participation rate was 62% for the MADT cohort and about 40% for the MIDT cohort.
Questionnaire data were available for 12449 individuals and lung function data were available for 11219
(90%) individuals. Participants with self-reported asthma were excluded (n=991), leaving 11458
individuals with questionnaire data; among these, lung function data were available for 10329 individuals.
Only individuals with questionnaire and lung function data were included, and thus 10329 individuals
were included in the analyses.
Questionnaire data
The participants completed a questionnaire at home, including questions on lifestyle factors, self-reported
physician-diagnosed diseases and respiratory symptoms, and brought the questionnaire to the clinical
examination. This was arranged to make the visit less time-consuming and ensure that the reported data
were not influenced by the presence of a physician or nurse. Respiratory symptoms included shortness of
breath at rest or during exercise, cough, chronic bronchitis (cough and sputum in ⩾3 months in two
consecutive years), nocturnal awakening due to shortness of breath and chest tightness.
Smoking
The participants were asked about smoking habits in terms of daily units smoked and duration of
smoking in years. Data were categorised into current, former and never-smokers. Pack-year exposure was
calculated as the average number of cigarettes smoked per day/20 × number of years smoked.
Clinical examination
Anthropometry
Height was measured twice with the participant standing in an upright position wearing no shoes, heels
together and head in the Frankfort position using a stadiometer and the average was recorded. Weight was
measured using an electronic scale (Soehnle, Backnang, Germany) with the participant wearing light clothing.
Spirometry and definition of airway obstruction
Lung function testing was performed using a Spiroson-AS ultrasonic flowmeter (ndd, Zurich, Switzerland),
which was calibrated prior to testing and with the participant in an upright sitting position wearing a nose
clip with at least three acceptable and two reproducible measurements according to ARS/ERS guidelines
for spirometry [24]. The Global Lung Initiative (GLI) 2012 reference values were used for FEV1, FVC and
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FEV1/FVC ratio [15]. The LLN-AO was defined in cases of an FEV1/FVC ratio <LLN corresponding to
the 2.5th centile (LLN 2.5%, z-score −1.96), as recommended for epidemiological studies [15], while the
FR-AO was defined in cases of an FEV1/FVC ratio <0.7 [2]. For the sake of comparison, we distinguished
between nonreversible airway obstruction (spirometrically defined) and clinical COPD (nonreversible
airway obstruction plus respiratory symptoms), the latter as recommend by the ATS/ERS guidelines [14].
In the assessment of the severity of airway obstruction we used the GOLD guidelines and the ERS/ATS
2005 grading system, in which a proposal for a new grading system is included [25]. An attempt to reduce
the misclassification of airway obstruction when using fixed FEV1/FVC ratio <0.7 is the “65/65” model, in
which a fixed ratio of 0.7 is used for individuals aged <65 years and a fixed ratio of 0.65 is used for
individuals aged >65 years, as suggested in the Swedish COPD guidelines [26].
For the baseline characteristics described in table 1 we distinguished between individuals with FR-AO only
(0.7>FEV1/FVC>LLN) and those with LLN-AO, whereas FR-AO in all other tables and figures refer to
those with FEV1/FVC<LLN.
Zygosity assessment
In same-sex twin pairs zygosity was determined based on a questionnaire method using four questions on
similarity. The overall misclassification rate using this method is as low as 4% when compared with
genetic marker analysis, and is thus regarded as a valid classification method [27].
Statistical analysis
Chi-squared tests and t-tests were used to compare the baseline characteristics in the healthy, LLN-AO and
FR-AO populations. Multiple logistic regressions were used to compare the risk of respiratory symptoms in
the two predefined populations with airway obstruction. Venn diagrams were created to illustrate the
overlap between the population with respiratory symptoms and the subgroups with airway obstruction
classified by different spirometric definitions. A categorical age variable was defined and the study sample
was divided into eight age groups: 40–44, 45–49, 50–54, 55–59, 60–64, 65–65, 70–74 and 75–80 years.
Data were analysed using the statistical package Stata 14.0 (StataCorp, College Station, TX, USA).
One assumption in regression analyses is that data are uncorrelated, and since data within a twin pair are
correlated, the CLUSTER option in Stata was added to the analyses, thereby ensuring this assumption was
fulfilled.
TABLE 1 Baseline characteristics of the total sample and subgroups of healthy population, fixed ratio only- and lower limit of
normal (LLN)-defined airway obstruction
Total
sample
Healthy
individuals#
Fixed ratio
only
LLN p-values
Healthy versus fixed
ratio only
Healthy versus
LLN
fixed ratio only
versus LLN
Subjects 10329 8475 1278 576
Males 5849 (48) 4067 (48) 673 (53) 265 (46) 0.002 0.36 0.008
Age years 58.4±9.6 57.5±9.4 63.3±8.7 60.0±9.3 <0.001 <0.001 <0.001
BMI
Overall kg·m-2 26.6±4.4 26.7±4.4 26.3±4.2 25.4±4.5 0.0013 <0.001 <0.001
Underweight 85 (1) 57 (1) 9 (1) 13 (2) 0.91 <0.001 <0.001
Normal weight 4320 (38) 3117 (37) 514 (40) 279 (49) 0.023 <0.001 0.001
Overweight 4868 (43) 3674 (44) 542 (43) 196 (34) 0.46 <0.001 <0.001
Obese 2097 (18) 1576 (19) 210 (16) 86 (15) 0.06 0.26 0.42
Smoking
Current
smokers
2273 (20) 1356 (16) 389 (31) 289 (50) <0.001 <0.001 <0.001
Former
smokers
4262 (37) 3134 (37) 514 (40) 194 (34) 0.032 0.11 0.009
Never-smokers 4842 (43) 3926 (47) 369 (29) 90 (16) <0.001 <0.001 <0.001
Pack-years 19.2±18.0 16.9±16.3 24.5±19.7 30.3±21.5 <0.001 <0.001 <0.001
Data are presented as n, n (%) or mean±SD, unless otherwise stated. BMI: body mass index. #: individuals who had completed spirometry
without fixed ratio airway obstruction (FR-AO) nor LLN-AO. The percentages are for available data and not the total number. p-values <0.0015
are emphasised in bold, as they meet significance after Bonferroni correction for multiple comparisons.
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Results
Table 1 presents the demographics for the 10329 individuals who had data available for analysis. Their
mean±SD age was 58.4±9.6 years, body mass index was 26.6±4.4 kg·m−2 and 48% were male. There was a
significant difference in age between the three subgroups, with the healthy population being the youngest
(57.5±9.4 years), followed by LLN-AO subjects (60.0±9.3 years) and FR-AO subjects were oldest
(63.3±8.7 years) (p<0.001). The proportion of current smokers differed significantly between the three
subgroups, being 16% for healthy individuals, 31% for FR-AO only and 50% for LLN-AO (p<0.001).
In the total sample, 26% reported respiratory symptoms and the prevalence of airway obstruction among
those with lung function data (n=10329) was 18.0% and 5.6% defined by fixed ratio and LLN, respectively
(p<0.001). Significantly more of the individuals with LLN-AO had respiratory symptoms compared with
the individuals with FR-AO (50% versus 39%, p<0.0001) (figure 1). The prevalence of clinical COPD was
2.6% and 6.3% when using the LLN and fixed ratio, respectively (p<0.001), while the prevalence of
self-reported physician-diagnosed COPD (PD-COPD) was 1.9%. There was a greater overlap between
PD-COPD and LLN-COPD than between PD-COPD and FR-COPD (27% versus 16%, p<0.001) (figure 2).
All individuals with LLN-AO also had FR-AO, but not vice versa. Figure 3a shows the distribution of
FEV1/FVC according to age in the whole population. The red dots represent those individuals with
LLN-AO and the yellow dots represent individuals with FR-AO, but above LLN. The figure shows that the
use of fixed ratio results in an overestimation of airway obstruction across all ages, but predominantly in
the oldest age group. Figure 3b shows the effect of the 65/65 model, which reduces but does not eliminate
the overestimation.
The difference in prevalence of FR-AO and LLN-AO increased with age. While the difference in
prevalence was 5.3% (8.0% versus 3.3, respectively) in the youngest age group (40–44 years), the difference
was 30.4% (38.2% versus 7.8%, respectively) in the oldest age group (75–80 years). The prevalence of
FR-AO ranged from 8.0% in the youngest group (40–44 years) to 38.2% in the oldest group (75–80 years),
whereas the prevalence of LLN-AO was <10% for all age groups (figure 4).
The association between respiratory symptoms and FR-AO and LLN-AO was assessed in multiple
logistic regressions adjusted for age, sex and ever-smoking (table 2). When compared to healthy
individuals, both groups with airway obstruction had a significantly higher risk of reporting respiratory
symptoms (model 1; p<0.001). In another analysis (model 2), comparing the groups FR-AO+LLN-AO-
Airway obstruction
(LLN for a selected population
z-score <–1.645)
n=946 (9.2%)
Airway obstruction
LLN (z-score <–1.96)
n=576 (5.6%)
Respiratory
symptoms
n=2998 (26.2%)
525 421
=45%
overlap**
=50%
overlap**
Airway obstruction
Fixed ratio FEV1/FVC <0.7
n=1854 (18%)
724
289
287
1130
=39%
overlap***
FIGURE 1 Venn diagram showing the overlap between the various spirometric definitions of airway obstruction
and respiratory symptoms. **: p<0.01 for difference between lower limit of normal (LLN) (for selected
population) versus fixed ratio; ***: p<0.001 for LLN versus fixed ratio.
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versus FR-AO+/LLN-AO+, we found that those with LLN-AO had a significantly higher risk of reporting
respiratory symptoms compared with those with FR-AO only.
Multivariate logistic regression analyses comparing the risk of respiratory symptoms and the various
definitions of airway obstruction in monozygotic twins versus dizygotic twins showed no difference except
for FR-AO (OR 1.17, 95% CI 1.03–1.34; p⩽0.02) (table 3). The distribution of individuals with airway
obstruction based on severity according to the GOLD guidelines, the ERS/ATS 2005 guidelines and the
proposed staging system from QUANJER et al. [25] are shown in table 4. The proportion of individuals with
respiratory symptoms in the different stages for each system was calculated and there was a significant
difference in symptom prevalence between the staging by GOLD, the ERS/ATS 2005 and the proposal
from QUANJER et al. in those individuals with mild and moderate airway obstruction. Allowing for GOLD
having fewer stages, the moderate and moderately severe staging for the other two systems were aggregated
and the symptom prevalence was 50% in moderate GOLD versus 59% and 63% in the ATS/ERS and
QUANJER et al. staging systems, respectively. GOLD identified fewer subjects in the worst category than the
other systems, and these subjects had fewer respiratory symptoms.
Sensitivity analyses
To explore the data further, we performed a number of sensitivity analyses. First, we estimated the
prevalence of airway obstruction when using the LLN with a z-score of −1.645, as appropriate for
patient-related data rather than population survey data. The prevalence of airway obstruction then
increased from 6.6% to 9.2%. In this case, the prevalence of FR-AO was still significantly higher, (18.0%
versus 9.2%, p=0.001). Likewise, the prevalence of clinical COPD increased from 2.5% to 3.8% and was still
significantly lower than FR-COPD (6.3%, p<0.001). Second, we observed no sex differences in prevalence
of LLN-AO and LLN-COPD, whereas a higher prevalence of FR-AO and FR-COPD was observed among
males compared with females (18.7% versus 17.2%, p=0.04 and 6.9% versus 5.9%, p=0.04, respectively).
Third, we defined FR-AO based on the 65/65 model. The prevalence of FR-AO then decreased from 18.0%
to 14.3%, but the overdiagnosis of airway obstruction in the oldest age group of the population was still
present. Last, we applied the same analyses as presented in tables 1, 2 and 4, defining the LLN as a z-score
FR-COPD
n=724 (6.3%)
LLN-COPD (–1.96)
n=289 (2.5%)
LL
N-
CO
PD
 (–
1.6
45
)
n=
42
1 (
3.7
%)
79
10
24S
elf
-re
po
rte
d
ph
ysi
cia
n-d
iag
no
sed
CO
PD
n=
21
3 (
1.9
%)
113/724 (16%) overlap#
89/421 (21%) overlap#
79/289 (27%) overlap#
FIGURE 2 Venn diagram showing the overlap between the various chronic obstructive pulmonary disease
(COPD) diagnoses: self-reported physician-diagnosed, fixed ratio (FR) and lower limit of normal (LLN).
#: p-values <0.001 for the difference in overlap between FR-COPD and LLN (−1.96) and 0.02 for the difference
in overlap between FR-COPD and LLN (−1.645).
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for FEV1/FVC-ratio <−1.645 for the sake of comparison with other studies. These analyses are shown in
online supplementary tables 1S, 2S and 3S, respectively.
Discussion
In this random population-based study of adult twins, we found a higher prevalence of airway obstruction
when using the fixed FEV1/FVC ratio <0.7 compared with FEV1/FVC ratio <LLN, which agrees with
0.7
0.8
0.9
1.0a)
0.6
0.5
0.4
0.3
FE
V1
/F
VC
 r
at
io
Age years
40 45 50 55 60 65 70 75 80
0.7
0.8
0.9
1.0b)
0.6
0.5
0.4
0.3
FE
V1
/F
VC
 r
at
io
Age years
40 45 50 55 60 65 70 75 80
Healthy individuals (no airway obstruction)
Fixed ratio overdiagnosis
FEV1/FVC <LLN (z-score <–1.96)
FIGURE 3 a) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age
showing individuals with FEV1/FVC ratio less than the lower limit of normal (LLN) (z-score <−1.96) and
potentially overdiagnosed individuals with the use of the fixed ratio; b) the proportion of potentially
overdiagnosed patients is reduced with the introduction of the 65/65 model, but overdiagnosis is still present.
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previous findings of the prevalence of FR-AO ranging from 10.9% to 21.3% [21, 22], the LLN-AO
(5.9–14.7%) [21, 22] and self-reported COPD (4.6–10.6%) [21, 28]. In addition, we found that the
difference in prevalence was more pronounced with increasing age, which is in line with other studies
comparing the impact of different spirometric definitions [11, 20]. Results from a Canadian study by VAN
DIJK et al. [11] are comparable to ours, suggesting the highest prevalence of airway obstruction in the
oldest age groups. However, a study by KARRASCH et al. [20] found the highest prevalence of LLN-AO in
the youngest age group (40–44 years) and the lowest among the oldest age group (>84 years), which is the
exact opposite of our findings; however, this study did not include symptoms in their diagnostic criteria.
In the present study we distinguished between the presence of airway obstruction only from clinical
COPD, which requires nonreversible airway obstruction and symptoms. When we compared clinical
COPD by fixed ratio and by LLN we found the highest prevalence was FR-COPD (6.3%), followed by
LLN-COPD (2.5%), and the lowest for self-reported PD-COPD (1.9%). Comparison of results with other
workers is complicated by the varying methodology and different definitions used in research and these
are an obvious explanation for the varying prevalence estimates. The case and disease definitions are not
always described systematically in the studies and make comparisons across studies uncertain [20, 21].
FIGURE 4 Prevalence of airway
obstruction in a random population
assessed by fixed ratio and lower
limit of normal (LLN) stratified by
age. Data are presented as odds
ratio (95% CI).
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TABLE 2 Associations between clinical outcomes and airway obstruction defined by fixed ratio (FR) and lower limit of normal
(LLN) and symptoms
Healthy
individuals
Model 1 Model 2
Airway obstruction Airway obstruction
Fixed ratio LLN FR+/LLN− (n=1278) (ref.)
versus
FR+/LLN+ (n=576)
Ref. (%) versus LLN (%)
Subjects n 8475 1854 576
Shortness of breath
At rest 180 (2.1) 1.00 66 (3.6) 1.62 (1.19–2.19) 31 (5.4) 2.33 (1.56–3.48) 2.8 versus 5.4 1.81 (1.11–2.94)
During daily activity# 52 (0.6) 1.00 33 (1.8) 2.49 (1.58–3.93) 17 (3.0) 4.34 (2.41–7.81) 1.3 versus 3.0 1.99 (0.98–4.1)
During exercise 849 (10.1) 1.00 359 (19.5) 2.02 (1.75–2.32) 176 (30.8) 3.77 (3.09–4.60) 14.5 versus 30.8 2.68 (2.09–3.43)
Chronic cough 529 (6.3) 1.00 285 (15.6) 2.42 (2.06–2.84) 144 (25.4) 4.36 (3.50–5.41) 11.2 versus 25.4 2.51 (1.93–3.26)
Chronic phlegm 369 (4.4) 1.00 211 (11.5) 2.42 (2.01–2.91) 114 (20.0) 4.47 (3.53–5.67) 7.7 versus 20.0 2.78 (2.06–3.75)
Chronic bronchitis¶ 232 (2.8) 1.00 146 (8.0) 2.67 (2.14–3.33) 85 (14.9) 5.19 (3.95–6.83) 4.8 versus 14.9 3.17 (2.22–4.53)
Nocturnal awakening 589 (7.0) 1.00 162 (8.7) 1.21 (1.00–1.46)+ 69 (12.0) 1.70 (1.29–2.23) 7.3 versus 12.0 1.65 (1.18–2.32)
Wheeze 305 (3.6) 1.00 215 (11.7) 3.08 (2.53–3.73) 115 (20.2) 5.57 (4.34–7.14) 7.9 versus 20.2 2.74 (2.03–3.70)
Data are presented as n (%) and odds ratio (95% CI), unless otherwise stated. Multiple logistic regression analysis adjusted for age (as a
dichotomous variable dividing the study sample at <60 years and ⩾60 years, sex, ever-smoking and body mass index. #: cleaning and dressing;
¶: defined according to American Thoracic Society/European Respiratory Society guidelines; +: p-value=0.044.
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Here, we have analysed data according to the recent recommendations for epidemiological studies from
ERS/ATS by defining the LLN as a z-score <−1.96 for FEV1/FVC ratio [15]. However, for the sake of
comparison we estimated the prevalence of airway obstruction with a LLN defined as a z-score <−1.645
for FEV1/FVC. This resulted in a higher prevalence of airway obstruction (from 5.6% to 9.2%), but which
was still significantly lower than the prevalence of FR-AO.
Several studies have reported that the use of LLN compared with fixed ratio results in underdiagnosis in
young individuals and overdiagnosis in the elderly [19, 29–31]. This study showed no underdiagnosis in
the youngest group, but substantial overdiagnosis was present across all age groups, and was predominant
in the elderly. However, when we defined the LLN as a z-score <−1.645, four young individuals were
underdiagnosed and 912 mainly older subjects were overdiagnosed. The poor overlap between those with
respiratory symptoms and those with either spirometric criteria could suggest that respiratory symptoms
are not especially related to airway obstruction, although the overlap was significantly greater in the group
with LLN-AO. The importance of labelling the patients correctly was evident in another Danish study
showing that the high mortality in those subjects with GOLD classification group B (who have minimal
TABLE 3 The risk of respiratory symptoms and airways obstruction (AO) in monozygotic versus
dizygotic twins
Monozygotic twins Dizygotic twins
Subjects Reference Subjects Crude OR Adjusted OR#
Respiratory symptoms
Shortness of breath
at rest 58 (2.4) 1.00 211 (2.5) 1.04 (0.78–1.41) 1.03 (0.76–1.38)
during daily activities¶ 25 (1.0) 1.00 73 (0.9) 0.84 (0.52–1.34) 0.77 (0.49–1.23)
during exercise 292 (11.8) 1.00 1019 (11.9) 1.00 (0.87–1.16) 0.96 (0.83–1.11)
Chronic cough 190 (7.8) 1.00 684 (8.0) 1.03 (0.87–1.23) 0.99 (0.83–1.18)
Chronic phlegm 130 (5.3) 1.00 507 (5.9) 1.13 (0.92–1.39) 1.08 (0.88–1.34)
Chronic bronchitis+ 83 (3.4) 1.00 328 (3.8) 1.14 (0.89–1.48) 1.11 (0.86–1.43)
Nocturnal awakening 194 (7.8) 1.00 606 (7.0) 0.89 (0.75–1.06) 0.87 (0.73–1.04)
Wheeze 131 (5.3) 1.00 450 (5.2) 0.98 (0.80–1.21) 0.95 (0.78–1.18)
Airway obstruction
FR 338 (15.2) 1.00 1470 (18.8) 1.29 (1.12–1.49) 1.18 (1.02–1.37)
LLN 109 (4.9) 1.00 451 (5.77) 1.19 (0.95–1.49) 1.14 (0.91–1.43)
Clinical COPD
FR-AO + symptoms 130 (5.2) 1.00 575 (6.6) 1.29 (1.05–1.59) 1.17 (0.95–1.44)
LLN-AO + symptoms 59 (2.4) 1.00 218 (2.5) 1.06 (0.78–1.44) 0.99 (0.73–1.34)
Data are presented as n (%) or odds ratio (OR) (95% CI). FR: fixed ratio; LLN: lower limit of normal; COPD:
chronic obstructive pulmonary disease. #: multiple logistic regression analysis adjusted for age (as a
dichotomous variable dividing the study sample at <60 years and ⩾60 years), sex and ever-smoking;
¶: cleaning, cooking and dressing; +: defined according to American Thoracic Society/European Respiratory
Society guidelines.
TABLE 4 Severity of airway obstruction according to different staging systems
GOLD [2] ATS/ERS [24] QUANJER [25]
Subjects Subjects at stage with
respiratory symptoms
Subjects Subjects at stage with
respiratory symptoms
Subjects Subjects at stage with
respiratory symptoms
Subjects n 1854 576 576
Mild 1045 (56) 283 (27) 292 (51) 98 (34) 307 (53) 104 (34)
Moderate 704 (38) 352 (50) 125 (22) 70 (56) 90 (16) 53 (59)
Moderately
severe
NA NA 73 (13) 47 (64) 90 (16) 59 (66)
Severe 90 (4.9) 76 (85) 59 (10) 48 (81) 69 (12) 54 (78)
Very severe 15 (1) 13 (87) 27 (5) 26 (96) 20 (3) 19 (95)
Data are presented as n (%), unless otherwise stated. GOLD: Global Initiative for Chronic Obstructive Pulmonary Disease; ATS: American
Thoracic Society; ERS: European Respiratory Society; NA: not applicable.
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airflow limitation, but experience symptoms) could be due to overlooked heart disease [13]. Comparison
between the different staging systems showed that a significantly higher proportion of individuals with
mild to moderate airway obstruction reported respiratory symptoms when graded either according to ATS/
ERS guidelines or the proposal from QUANJER et al. [25] as compared to GOLD staging.
The multivariate logistic regression analyses showed that the risk of respiratory symptoms was increased in
individuals with FR-AO compared with healthy individuals but this was seen to a greater extent in
individuals with LLN-AO. This was evident in a further analysis comparing individuals with both FR-AO
and LLN-AO with those with only FR-AO, suggesting that the use of LLN will result in a better
identification of individuals with characteristic symptoms of COPD.
The prevalence of respiratory symptoms and LLN-AO in monozygotic and dizygotic twins was similar,
whereas a higher prevalence of FR-AO was observed in dizygotic twins. A random twin population can be
considered representative of the general population with regards to lung function. Studies have shown that
lung function data from twin individuals display the same pattern as data from singleton individuals [32, 33].
A significantly lower prevalence of overweight and obesity was observed in individuals with airway
obstruction compared with healthy individuals, which could be explained by the significantly higher
proportion of current smokers among these individuals. Furthermore, this would explain the lower
prevalence of overweight individuals in the LLN-AO group, as the prevalence of current smokers is higher
than is in the fixed ratio-only group.
This study has a number of strengths. First, we included individuals from a very large nationwide
population with an age span of 40–80 years. Second, compared to similar studies, this is the largest study
with both questionnaire and spirometry data. Third, we have recorded the spirometry using the best
available ultrasonic flowmeter with bespoke software, we used the comprehensive GLI-2012 reference
values and followed the latest recommendations from ATS/ERS for epidemiological studies. Last, we
performed sensitivity analyses to test the robustness of our data and to enable comparison for current and
future studies.
A limitation of this study is that we only obtained prebronchodilator spirometry and thereby introduced a
small risk of overestimating the presence of airway obstruction, which according to GOLD guidelines
should be based on postbronchodilator spirometry [34]. However, we excluded all individuals with
self-reported physician-diagnosed asthma, which has been shown to reduce the risk of overestimation [35]
and any overestimation will affect both definitions of airway obstruction. Another limitation is low
response rate among the MIDT cohort. This has previously been explained by three possible factors: as
subjects in the MIDT cohort were younger, a higher proportion of them were still in their active work life;
2) they had to travel to one of the three examination facilities, meaning a longer journey for those living
far away from the major cities; and 3) they have not been approached as often as those from the MADT
follow-up study [23]. Furthermore, in a cross-sectional study, it is not possible to predict outcomes based
on the different spirometric criteria.
Conclusion
In this large, nationwide population study of adults aged 40–80 years, we found that the use of the fixed
ratio criterion for FEV1/FVC in diagnosing airflow obstruction resulted in a higher prevalence of airway
obstruction as opposed to the LLN criterion and that the difference increased with age. The prevalence of
respiratory symptoms was significantly increased among individuals with both LLN-AO and FR-AO
compared with those with FR-AO only. A significantly higher proportion of those with mild to moderate
airway obstruction have respiratory symptoms when graded according to ATS/ERS guidelines compared
with GOLD guidelines.
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